Compass Pathways Aktie

Compass Pathways AAQS

AAQS'en for Compass Pathways (CMPS) pr. 4. aug. 2026 er 4. I foregående år var AAQS'en 4,00 — en ændring på 0,00 % (lavere).

AAQS

4

YoY

0,00%

Senest opdateret:

Compass Pathways har en aktuel AAQS på 4. En høj AAQS kan betragtes som et positivt tegn på, at virksomheden udvikler sig succesfuldt. Investorerne kan forvente, at virksomheden er på rette spor mod at skabe overskud. På den anden side er det vigtigt at betragte AAQS for aktien Compass Pathways i forhold til de opnåede overskud og sammenligne med andre virksomheder i samme branche. En høj AAQS er ikke en absolut garanti for en positiv fremtid. Det er kun på den måde, man kan få et komplet billede af virksomhedens præstationer. For bedre at kunne vurdere virksomhedens udvikling er det vigtigt at betragte AAQS i sammenligning med andre virksomheder i samme branche. Generelt bør investorer altid betragte en virksomheds AAQS i sammenhæng med andre nøgletal som overskud, EBIT, cash flow og andre for at træffe en velbaseret investeringsbeslutning.
Access this data via the Eulerpool API

Compass Pathways Aktieanalyse

Hvad laver Compass Pathways? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Compass Pathways aktie

AAQS'en for Compass Pathways er 4 i 2026.

På Eulerpool kan du finde den fuldstændige historiske udvikling af AAQS'en Compass Pathways siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

AAQS er en nøgletal udviklet af AlleAktien.

AAQS er en nøgletal udviklet af AlleAktien.

Access this data via the Eulerpool API

Kvalitet — Compass Pathways

Alle nøgletal — Compass Pathways